Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study by Jasmijn D. E. de Rooij, Riccardo.

Slides:

Advertisements

Similar presentations

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL by Arian.

Advertisements

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia by Jose Claudio C. Rocha, Cheng Cheng, Wei Liu, Shinji Kishi, Soma Das, Edwin.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

HOXA9 is required for survival in human MLL-rearranged acute leukemias by Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis,

Electroejaculation as a method of fertility preservation in boys diagnosed with cancer: a single-center experience and review of the literature Maria.

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study by Martin Schrappe, Maria.

Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21 by Liat Rainis, Dan Bercovich, Sabine Strehl, Andrea.

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma by Jean-Louis H. Kerkhoffs,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide.

One giant leap for pediatric AMKL

How I treat elderly patients with myeloma

Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective.

Nonmyeloablative conditioning for relapsed follicular lymphoma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.

Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents by Marcin W. Wlodarski, Shinsuke.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Nat. Rev. Urol. doi: /nrurol

Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive.

A novel hierarchical prognostic model of AML solely based on molecular mutations by Vera Grossmann, Susanne Schnittger, Alexander Kohlmann, Christiane.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Stage C or not stage C…? by Claire Dearden Blood

Primary testicular lymphoma

Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia by Davide Rossi, Silvia Rasi, Valeria.

Ivana M. M. van der Geest, BSc, Anne-Sophie E

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and.

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies by Brigitte T. A. van den Broek, Kristin.

Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL by Lina Hamadeh, Amir Enshaei, Claire Schwab,

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Electroejaculation as a method of fertility preservation in boys diagnosed with cancer: a single-center experience and review of the literature Maria.

BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1–positive B-cell acute lymphoblastic leukemia by Karen A. Dun, Rob Vanhaeften, Tracey J.

Nat. Rev. Urol. doi: /nrurol

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

2017 ELN Risk Stratification by Genetics

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Durability of response after horse ATG

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

Survival of children with sickle cell disease

Patient stratification using survival risk prediction and BCLC staging

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Two major molecular subgroups within PTCL-NOS with biological and overall survival differences. Two major molecular subgroups within PTCL-NOS with biological.

Cold agglutinin disease

Outcomes in patients with PTCL

Presentation transcript:

Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study by Jasmijn D. E. de Rooij, Riccardo Masetti, Marry M. van den Heuvel-Eibrink, Jean-Michel Cayuela, Jan Trka, Dirk Reinhardt, Mareike Rasche, Edwin Sonneveld, Todd A. Alonzo, Maarten Fornerod, Martin Zimmermann, Martina Pigazzi, Rob Pieters, Soheil Meshinchi, C. Michel Zwaan, and Franco Locatelli Blood Volume 127(26):3424-3430 June 30, 2016 ©2016 by American Society of Hematology

Overview of cytogenetic aberrations and aberrations found in the karyotypes of pediatric AMKL (n = 153). Overview of cytogenetic aberrations and aberrations found in the karyotypes of pediatric AMKL (n = 153). Each column represents a single case. A colored cells means positive for the aberration corresponding with that particular row. X indicates that the karyotype is not available, the only information given is hyperdiploid, or complex karyotype. -13/13q, monosomy 13 or del(13q); NA, not available. Jasmijn D. E. de Rooij et al. Blood 2016;127:3424-3430 ©2016 by American Society of Hematology

Survival curves of pediatric AMKL patients. Survival curves of pediatric AMKL patients. The 4-year pEFS (A), 4-year pOS (B), and 4-year pCIR (C) comparing the outcome of patients of the different enrolled study groups. There is no significant difference in outcome among the study groups. The 4-year pEFS (D), 4-year pOS (E), and 4-year pCIR (F) comparing the described cytogenetic subgroups as identified in pediatric non-Down syndrome AMKL. RBM15/MKL1-positive cases and other pediatric AMKL have a favorable outcome compared with NUP98/KDM5A, CBFA2T3/GLIS, KMT2A rearrangements and monosomy 7 cases. The 4-year pEFS (G), 4-year pOS (H), and 4-year pCIR (I) of the NUP98/KDM5A, CBFA2T3/GLIS2, KMT2A rearrangements and monosomy 7 cases compared with the RBM15/MKL1 and other pediatric AMKL cases. Harboring NUP98/KDM5A, CBFA2T3/GLIS2, KMT2A rearrangements or monosomy 7 confers a poor outcome. Jasmijn D. E. de Rooij et al. Blood 2016;127:3424-3430 ©2016 by American Society of Hematology